2-Amino-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-6-fluorobenzenesulfonamide
- CAS
- 2017554-98-0
- Formula
- C23H22F2N6O2S2
- MW
- 516.6 g/mol
VQ-022294
Impurity reference standards
Dabrafenib impurities & reference standards
Characterised Dabrafenib impurities, degradation products and related compounds for analytical method development, validation, QC release and regulatory filings.
22reference materials
1isotope-labelled
COAHPLC · NMR · MS on request
Parent API: Dabrafenib
1195765-45-7 · C23H20F3N5O2S2
Methyl 3-((2,6-difluorophenyl)sulfonamido)-2-fluorobenzoate
- CAS
- 1195768-19-4
- Formula
- C14H10F3NO4S
- MW
- 345.3 g/mol
VQ-025145
N-(3-(2-(2-Chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
- CAS
- 1195768-20-7
- Formula
- C18H11ClF3N3O3S
- MW
- 441.8 g/mol
VQ-025147
N-(3-(2-(Tert-Butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
- CAS
- 1195768-23-0
- Formula
- C23H18ClF3N4O2S2
- MW
- 539 g/mol
VQ-025148
FAQs — Dabrafenib impurities
Which Dabrafenib impurities do you supply?
We list 22 Dabrafenib-related reference materials, including process impurities, degradation products, stable-isotope-labelled standards and related compounds. Each is supplied with a COA, and characterisation data (HPLC, 1H-NMR, MS, IR) can be provided on request.
What are Dabrafenib impurity standards used for?
They are used for analytical method development and validation, impurity identification and quantification, forced-degradation and stability studies, and to support ANDA, DMF and other regulatory submissions under ICH Q3A/Q3B (and ICH M7 for mutagenic impurities).
Can you synthesise a Dabrafenib impurity that is not listed?
Yes. Our custom synthesis service can prepare and characterise unlisted impurities, metabolites and labelled analogues from milligram to gram scale. Share the structure or name and required quantity for a quotation.
Request Dabrafenib impurity standards
We reply within one business day with price, pack options, lead time and documentation.